Yposkesi is the largest European CDMO for gene therapy vector manufacturing. Created in November 2016 in Corbeil Essonnes (France) as a spin off from the world-class gene therapy pioneer Genethon, Yposkesi provides a full-service offer covering BioProcess development (USP & DSP), from small/pilot to large production scale, analytical development, GMP manufacturing of clinical lots of lentiviral vectors.
Its current facility consists in a 50,000 sq ft building, operating 4 manufacturing suites for bulk drug substance, and 2 Fill & Finish suites. This capacity will be expanded in 2021 with a large scale facility (50,000 sq ft) equipped with 2*1,000L bioreactors, designed for commercial production and compliant to EMA and FDA. Capitalizing on more than 25 years of expertise, Yposkesi significantly invests in innovation in bioprocessing to cost-effectively deliver on high quality projects.